Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

AB SCIEX and Dalton Collaborate to Advance ADC Analysis

Published: Friday, August 29, 2014
Last Updated: Friday, August 29, 2014
Bookmark and Share
Collaboration supports movement to develop targeted anti-body based therapies.

AB SCIEX and Dalton Pharma Services (Dalton) have announced a research collaboration to develop Antibody-Drug Conjugate (ADC) analysis capabilities. This will include development of more definitive and comprehensive method for the identification of drug loading and position of conjugation on macromolecules.

This collaboration is part of AB SCIEX's commitment to support the growing movement to bring targeted antibody-based therapies to market.

Our collective goal is to help our customers bring drugs from concept to market faster. The collaboration provides AB SCIEX, a global leader in life science analytical technologies, with the specialized synthetic conjugation capabilities of Dalton.

The research includes the preparation and characterization of ADC's by Dalton scientists working with AB SCIEX experts to develop standardized analytical procedures on the TripleTOF® 5600+ system with SelexION™ technology and the new TripleTOF® 6600 platform for determining the chemical structures of conjugated molecules.

"A key challenge for developing successful Antibody-Drug Conjugate medicines is understanding the structure and payload of the final molecule. Determining where the drug attaches to a particular antibody early in its development and the number of drug molecules on the antibody are important indicators of the likely success of a new ADC," explained Tan Quach, Chemistry Manager at Dalton Pharma Services.

"Recent advances in mass spectrometry have provided a solution to answer the challenging questions in terms of understanding ADC drug development and working within a biological matrix," said Chris Radloff, Vice President, LC/ MS Business at AB SCIEX. "Utilizing these molecules is difficult and by forming this partnership, ADC developers can now reduce complications, and obtain accurate results that will ultimately lead to safer, more effective therapies."

Results of the first phase of the collaboration were featured at ASMS 2014 in Baltimore. The partnership will continue to co-develop standardized analytical procedures utilizing the MS technology that delivers consistent results when compared with ELISA and publish technical papers over the next upcoming months.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Collaboration to Develop Cannabis Testing Standards
SCIEX workflow solution enables cannabis labs to ensure product safety with robust, cost-effective analytical methods to facilitate routine testing.
Tuesday, September 13, 2016
SCIEX Works with the Francis Crick Institute and the University of Cambridge
New proteomic study to develop advanced resource for precision medicine research by using Microflow SWATH® Acquisition for HT industrialized proteomics.
Wednesday, June 29, 2016
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
Friday, June 17, 2016
SCIEX, QPS Holdings Collaborate
Agreement aims to advance the hybrid LBA-LCMS workflow for biologics quantification.
Wednesday, April 06, 2016
SCIEX, Children's Medical Research Institute Collaborate
SCIEX industrialized proteomics solutions, using SWATH® Acquisition-based workflows and powered by the OneOmics™ Project, will enable large scale proteome studies to advance cancer research.
Thursday, February 11, 2016
SCIEX, A*STAR’s BTI Launch Collaboration
Agreement aims to boost innovation of protein drugs that target new diseases and are safer for patients.
Wednesday, January 27, 2016
SCIEX, Pressure BioSciences Partner
SCIEX and Pressure BioSciences to offer complete solution for next-generation proteomics, to increase the reproducibility and depth of proteomic analysis.
Wednesday, January 13, 2016
SCIEX, University of Manchester Partner
SWATH® Acquisition-based next-generation proteomics technology promises to make industrial proteomics a reality.
Thursday, October 29, 2015
SCIEX Partners with the Paulovich Lab at Fred Hutchinson Cancer Research Center
Collaboration targets research reproducibility crisis with highly validated multiplex quantitation assays.
Wednesday, September 23, 2015
SCIEX and New Objective Announce Partnership
New nanospray sources to offer maximum sensitivity and robustness for NanoLC-MS.
Tuesday, June 02, 2015
SCIEX and New Objective Partner
Partnership will provide advanced nanospray ionization technologies for next-generation proteomics.
Tuesday, May 26, 2015
SCIEX and Hepregen Announce Co-Marketing Agreement
Alliance establishes SCIEX and Hepregen as a one-stop solution provider for drug metabolism investigators.
Friday, May 22, 2015
Sciex, Hepregen Team up on Metabolite Identification Offering
This recently announced collaboration aims to provide practical solutions for drug metabolism researchers.
Thursday, May 21, 2015
Dr. Gyula Vigh wins Arnold O. Beckman Award
SCIEX sponsored award recognizes outstanding contributions to the field of electrodriven separation techniques.
Thursday, May 07, 2015
SCIEX and Mass Consortium Corporation Announce Exclusive Reseller Agreement
SCIEX to provide customers with XCMSplus software solution for simplified and accelerated metabolomics workflows.
Tuesday, March 31, 2015
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos